IL6 Antibody

What is IL-6 and why is it a significant target for antibody development?

IL-6 is a pleiotropic cytokine initially identified in 1973 as a soluble factor secreted by T cells that plays a crucial role in antibody production by B cells. Over the past four decades, IL-6 has emerged as a pivotal pathway involved in immune regulation in health and dysregulation in numerous diseases. Its significance as a therapeutic target stems from its central role in various rheumatic diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, giant cell arteritis, and Takayasu arteritis . Additionally, IL-6 targeting has shown promise in conditions such as Castleman disease, cytokine release syndrome, uveitis, neuromyelitis optica, and COVID-19 pneumonia .

How do IL-6 antibodies function at the molecular level?

IL-6 antibodies function by specifically binding to IL-6 molecules, thereby preventing their interaction with IL-6 receptors (IL-6R). This blocking mechanism inhibits the downstream signaling cascade that would normally be initiated upon IL-6 binding to its receptor. At the molecular level, anti-IL-6 antibodies like HZ-0408b bind to IL-6 with high affinity (as measured by equilibrium dissociation constant, KD) and effectively block the interaction between IL-6 and IL-6R in a dose-dependent manner . This inhibition prevents the activation of the JAK-STAT3 signaling pathway, which is a key mediator of IL-6 biological effects, such as the induction of acute phase proteins like serum amyloid A (SAA) in the liver .

What are the primary methods for testing IL-6 antibody binding and specificity?

The primary methods for testing IL-6 antibody binding and specificity include:

• ELISA (Enzyme-Linked Immunosorbent Assay): Plates are coated with recombinant human IL-6 protein (such as rhIL-6-His fusion protein), and the binding of anti-IL-6 antibodies is detected using an HRP-conjugated secondary antibody . This method allows for quantitative assessment of antibody binding affinity in a dose-dependent manner.

• Bio-layer Interferometry (BLI): This technique measures real-time binding kinetics between the antibody and IL-6. Anti-human Fc Capture biosensors are used to probe purified antibodies, and the association and dissociation kinetics of binding to rhIL-6-His are measured to calculate the equilibrium dissociation constant (KD), association constant (Ka), and dissociation constant (Kd) .

• Competition ELISA: This assay determines whether two antibodies recognize the same or different epitopes on IL-6 by measuring competitive binding .

• Western blot analysis: Denatured IL-6 protein is subjected to SDS-PAGE, and anti-IL-6 antibodies are used as primary antibodies to determine if they recognize linear epitopes .

How are IL-6 neutralizing antibodies evaluated for functional activity?

Functional activity of IL-6 neutralizing antibodies is evaluated through several approaches:

• Inhibition of IL-6/IL-6R interaction: IL-6R-coated plates are used to measure the ability of antibodies to block the binding of IL-6 to its receptor. This is typically quantified by ELISA with increasing concentrations of antibody .

• Inhibition of STAT3 phosphorylation: Since IL-6 signaling activates the JAK-STAT3 pathway, researchers measure the phosphorylation of STAT3 (p-STAT3) by western blot in cell lines such as DLD-1 treated with IL-6 in the presence or absence of anti-IL-6 antibodies .

• Inhibition of downstream biological effects: For example, measuring the inhibition of IL-6-induced serum amyloid A (SAA) secretion in hepatic cell lines like HepG2. SAA is an acute phase protein dramatically increased during inflammation and is a precursor of amyloid A protein in secondary amyloidosis, a serious complication of chronic inflammatory diseases .

• Cell proliferation assays: IL-6-dependent cell lines such as DS-1 (a B lymphoblastoid cell line) are used to assess the ability of anti-IL-6 antibodies to inhibit IL-6-driven cell proliferation .

What considerations are important when designing experiments to compare different IL-6 antibody clones?

When designing experiments to compare different IL-6 antibody clones, several critical considerations must be addressed:

• Standardization of antibody concentrations: Ensure equimolar concentrations of different antibodies are used to allow direct comparisons of binding affinities and functional effects.

• Selection of appropriate controls: Include both positive controls (commercially validated antibodies like Siltuximab) and negative controls (isotype-matched antibodies with irrelevant specificity) .

• Multiple functional readouts: Employ various functional assays to comprehensively evaluate antibody performance, including binding assays (ELISA, BLI), signaling inhibition assays (p-STAT3 levels), and downstream functional effects (SAA secretion, cell proliferation) .

• Dose-response analyses: Test antibodies across a range of concentrations to determine IC50 values, which provide quantitative measures of potency that can be compared across different antibody clones .

• Epitope characterization: Determine whether antibodies recognize linear or conformational epitopes, and whether different antibodies compete for the same binding site, which can provide insights into their mechanisms of action .

• Species cross-reactivity assessment: Evaluate binding to IL-6 from different species to determine the specificity and potential applications in preclinical animal models .

How can researchers accurately measure the binding affinity and kinetics of IL-6 antibodies?

Researchers can accurately measure binding affinity and kinetics of IL-6 antibodies through several sophisticated techniques:

• Bio-layer Interferometry (BLI): This label-free technology measures real-time biomolecular interactions by analyzing the interference pattern of white light reflected from the surface of a biosensor tip. For IL-6 antibodies, Anti-human Fc Capture (AHC) biosensors can be used to immobilize antibodies, and the association and dissociation of IL-6 can be monitored in real-time . The data are fitted to a 1:1 binding model to calculate:

  • Equilibrium dissociation constant (KD)

  • Association constant (Ka)

  • Dissociation constant (Kd)

• Surface Plasmon Resonance (SPR): Similar to BLI, SPR provides real-time kinetic measurements of antibody-antigen interactions.

• Isothermal Titration Calorimetry (ITC): Measures the heat released or absorbed during antibody-antigen binding to provide thermodynamic parameters in addition to binding constants.

For example, the HZ-0408b antibody demonstrated a KD of 1.075e-9 M for IL-6, which was ten times lower than that of Siltuximab (1.168e-8 M), indicating higher affinity. The difference was primarily due to a higher association constant (Ka) of HZ-0408b (2.333e5 1/Ms) compared to Siltuximab (2.052e4 1/Ms), while dissociation constants were similar (2.507e-4 1/s vs. 2.396e-4 1/s) .

What cell-based assays are most effective for evaluating IL-6 antibody neutralizing activity?

Several cell-based assays have proven effective for evaluating the neutralizing activity of IL-6 antibodies:

• STAT3 phosphorylation assay: DLD-1 cells (human colorectal adenocarcinoma) are treated with IL-6 in the presence or absence of anti-IL-6 antibodies, and the inhibition of STAT3 phosphorylation at tyrosine 705 is measured by western blot . This assay directly assesses the ability of antibodies to block the primary signaling pathway activated by IL-6.

• SAA induction assay: HepG2 cells (human hepatocellular carcinoma) are stimulated with IL-6 and IL-1β to induce SAA production. The ability of anti-IL-6 antibodies to inhibit SAA secretion is measured by ELISA . This assay evaluates the downstream biological effects of IL-6 signaling inhibition.

• IL-6-dependent cell proliferation assay: DS-1 cells (IL-6-dependent B lymphoblastoid cells) are incubated with IL-6 in the presence of serial dilutions of anti-IL-6 antibodies, and cell proliferation is measured . This assay assesses the functional consequence of IL-6 neutralization on cellular growth.

• IL-6-induced acute phase protein expression: Besides SAA, other acute phase proteins induced by IL-6 in hepatocytes can be measured, such as C-reactive protein (CRP) and fibrinogen.

How can researchers distinguish between antibodies that target IL-6 versus those that target the IL-6 receptor?

Distinguishing between antibodies that target IL-6 versus those that target the IL-6 receptor (IL-6R) requires specific experimental approaches:

• Target-specific binding assays: ELISA plates coated separately with recombinant IL-6 or IL-6R can determine whether an antibody binds directly to IL-6 or to IL-6R .

• Competition assays:

  • For anti-IL-6 antibodies: Pre-incubation of IL-6 with the antibody should prevent IL-6 binding to plate-coated IL-6R.

  • For anti-IL-6R antibodies: Pre-incubation of IL-6R with the antibody should prevent IL-6 binding to plate-coated IL-6R.

• Inhibition mechanism analysis:

  • Anti-IL-6 antibodies prevent IL-6 from binding to its receptor by binding directly to IL-6.

  • Anti-IL-6R antibodies block the binding site on the receptor, preventing IL-6 from interacting with IL-6R.

• Cell-based assays with receptor overexpression: Comparing antibody effects in cells with normal versus overexpressed IL-6R can help distinguish the mechanism of action. Anti-IL-6R antibodies may show reduced efficacy in cells with high IL-6R expression due to competitive binding, while anti-IL-6 antibodies' efficacy would depend primarily on the amount of IL-6 present.

How do IL-6 antibodies differ in their therapeutic applications compared to other cytokine-targeting approaches?

IL-6 antibodies offer several distinct advantages and considerations in therapeutic applications compared to other cytokine-targeting approaches:

• Specific signaling pathway inhibition: Unlike broad-spectrum anti-inflammatory agents, IL-6 antibodies specifically target the IL-6 signaling pathway, which is crucial in numerous inflammatory and autoimmune conditions. This targeted approach can potentially reduce off-target effects compared to broader immunosuppressive therapies .

• Dual signaling blockade: IL-6 signals through both membrane-bound receptors (classical signaling) and soluble receptors (trans-signaling). Anti-IL-6 antibodies like Siltuximab block both signaling modes by binding directly to IL-6, whereas anti-IL-6R antibodies primarily block the interaction of IL-6 with its receptor .

• Diverse disease applications: IL-6 targeting has demonstrated efficacy in a wide range of diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, giant cell arteritis, Takayasu arteritis, Castleman disease, and cytokine release syndrome . Recent research has also explored its potential in uveitis, neuromyelitis optica, and COVID-19 pneumonia .

• Differential effects on immune components: Compared to TNF inhibitors, which broadly affect multiple immune pathways, IL-6 blockade has more specific effects on certain aspects of immunity, such as B-cell functions, acute phase protein production, and Th17 differentiation .

• Complementary targeting: In some cases, IL-6 blockade can be effective in patients who have failed other cytokine-targeted therapies, suggesting non-overlapping mechanisms of action that can be leveraged in treatment strategies .

What are the key considerations for using IL-6 antibodies in in vitro versus in vivo research models?

When using IL-6 antibodies in research, several key considerations differ between in vitro and in vivo models:

In vitro considerations:

• Antibody concentration optimization: Careful titration of antibody concentrations is necessary to establish dose-response relationships in cell-based assays .

• Cell line selection: Different cell lines may exhibit varying sensitivities to IL-6 stimulation and antibody inhibition. For example, DLD-1 cells are used for STAT3 phosphorylation assays, HepG2 cells for SAA induction, and DS-1 cells for proliferation assays .

• Serum presence: Serum components may interfere with antibody-antigen interactions or contain endogenous IL-6, potentially affecting experimental outcomes.

• Timing of antibody addition: Pre-incubation of antibodies with IL-6 versus simultaneous addition to cells may yield different results.

In vivo considerations:

• Antibody half-life and biodistribution: The pharmacokinetic properties of antibodies, including half-life in circulation and tissue penetration, significantly impact in vivo efficacy.

• Species cross-reactivity: Many antibodies are species-specific, necessitating careful selection of antibodies that recognize the IL-6 of the animal model being used .

• Immunogenicity: Humanized antibodies may elicit immune responses in animal models, potentially neutralizing the antibody or causing adverse reactions.

• Dosing regimen: The timing, frequency, and route of antibody administration must be optimized for in vivo models to achieve consistent IL-6 neutralization.

• Readout selection: Appropriate biomarkers must be selected to assess in vivo efficacy, such as serum levels of acute phase proteins or clinical scores in disease models.

How can researchers troubleshoot inconsistent results in IL-6 antibody neutralization assays?

Inconsistent results in IL-6 antibody neutralization assays can stem from various sources. Here are key troubleshooting approaches:

• Antibody quality assessment:

  • Check antibody stability and storage conditions

  • Verify antibody concentration and purity

  • Consider using multiple antibody lots to identify lot-to-lot variability

• IL-6 source and quality:

  • Ensure consistent quality of recombinant IL-6

  • Test different lots of IL-6 to identify potential variability

  • Consider the species origin of IL-6 and ensure it matches the antibody's specificity

• Cell culture conditions:

  • Maintain consistent cell passage numbers and confluence

  • Standardize serum lots and concentrations

  • Control for endogenous IL-6 production by the cells

• Assay optimization:

  • Establish clear dose-response curves for IL-6 stimulation

  • Determine the optimal timing for IL-6 stimulation and antibody addition

  • Include appropriate positive and negative controls in each experiment

• Signal detection methods:

  • For western blot-based detection of phosphorylated STAT3, optimize lysis conditions and ensure consistent protein loading

  • For ELISA-based readouts, verify reagent quality and optimize washing and blocking steps

• Data analysis approaches:

  • Use IC50 values rather than single-point measurements to compare antibody potency

  • Perform statistical analyses with appropriate replicates

  • Consider normalizing data to internal controls to account for inter-assay variability

What novel applications of IL-6 antibodies are emerging in current research?

Recent research has identified several novel and promising applications for IL-6 antibodies:

• COVID-19 treatment: IL-6 has been implicated in the cytokine storm associated with severe COVID-19. Anti-IL-6 therapies are being investigated for their potential to mitigate this hyperinflammatory response and improve outcomes in severe COVID-19 cases .

• Neuromyelitis optica: This rare autoimmune disorder affecting the optic nerves and spinal cord shows elevated IL-6 levels. Preliminary research suggests IL-6 blockade may be beneficial in this condition .

• Uveitis: IL-6 plays a role in ocular inflammatory diseases, and IL-6 blockade is being explored as a potential treatment approach for refractory uveitis .

• Cancer immunotherapy combinations: Emerging research is investigating the combination of IL-6 blockade with immune checkpoint inhibitors to enhance anti-tumor immune responses by modulating the tumor microenvironment.

• Fibrotic diseases: IL-6 contributes to fibroblast activation and extracellular matrix production. Anti-IL-6 therapies are being explored for conditions characterized by excessive fibrosis, such as systemic sclerosis and idiopathic pulmonary fibrosis.

• Metabolic inflammation: IL-6 links inflammation to metabolic dysregulation. Research is investigating IL-6 blockade for conditions like type 2 diabetes and non-alcoholic steatohepatitis (NASH).

How can researchers accurately compare the efficacy of different IL-6 antibody clones?

Accurately comparing the efficacy of different IL-6 antibody clones requires a systematic approach with standardized methods:

• Standardized binding assays:

  • Implement side-by-side ELISA assays with identical conditions for all antibodies

  • Use Bio-layer Interferometry (BLI) or Surface Plasmon Resonance (SPR) to quantitatively compare binding kinetics (Ka, Kd) and affinity (KD)

  • Perform competition assays to determine if antibodies recognize the same or different epitopes

• Functional comparison framework:

  • Establish a panel of standardized assays covering different aspects of IL-6 biology

  • Include direct binding to IL-6, inhibition of IL-6/IL-6R interaction, STAT3 phosphorylation, and downstream functional effects

  • Generate complete dose-response curves to calculate IC50 values for each antibody in each assay

• Comparative metrics table:

This systematic comparison reveals that HZ-0408b has approximately 10-fold higher binding affinity than Siltuximab, primarily due to a faster association rate, and is more potent in inhibiting SAA secretion with an IC50 approximately 7-fold lower than Siltuximab .

What are the best practices for optimizing IL-6 antibody concentrations in experimental designs?

Optimizing IL-6 antibody concentrations in experimental designs involves several best practices:

• Initial range-finding experiments:

  • Begin with a wide concentration range (e.g., 0.01-100 μg/ml) to identify the dynamic range of antibody effects

  • Use logarithmic dilution series (e.g., 10-fold dilutions) for efficient coverage of a wide concentration range

• Dose-response curve generation:

  • Once the approximate effective range is identified, perform more focused experiments with narrower concentration intervals

  • Use at least 6-8 antibody concentrations to generate reliable dose-response curves

  • Include concentrations that span from no effect (<10% inhibition) to maximum effect (>90% inhibition)

• Statistical considerations:

  • Perform experiments with at least three biological replicates

  • Use appropriate curve-fitting software to calculate IC50 values with confidence intervals

  • Consider using four-parameter logistic regression for sigmoidal dose-response curves

• System-specific optimization:

  • Different experimental systems may require different antibody concentrations

  • For STAT3 phosphorylation assays in DLD-1 cells, effective concentrations may range from 1-10 μg/ml

  • For SAA inhibition in HepG2 cells, concentrations of 0.1-30 μg/ml might be appropriate

  • For IL-6-dependent cell proliferation assays, the effective range could be 0.01-10 μg/ml

• Consideration of IL-6 concentration:

  • The ratio of antibody to IL-6 is critical - ensure that antibody concentrations are titrated against a fixed, physiologically relevant IL-6 concentration

  • For in vitro assays, 10-20 ng/ml IL-6 is often used for stimulation, requiring proportionate antibody levels

How can researchers effectively validate the specificity of IL-6 antibodies?

Effective validation of IL-6 antibody specificity involves multiple complementary approaches:

• Cross-reactivity testing:

  • Test antibody binding to related cytokines (e.g., IL-11, LIF, OSM) that share receptor components with IL-6

  • Perform ELISA or western blot assays with a panel of recombinant cytokines to confirm specificity

• Species cross-reactivity assessment:

  • Test binding to IL-6 from different species (human, mouse, rat, non-human primates)

  • Important for selecting appropriate models for translational research

• Competitive inhibition assays:

  • Perform competition assays with known specific anti-IL-6 antibodies (e.g., Siltuximab)

  • If two antibodies compete for binding, they likely recognize the same or overlapping epitopes

• Blocking controls in functional assays:

  • Include IL-6R blockers as alternative controls in functional assays

  • If an effect is truly IL-6-specific, both anti-IL-6 and anti-IL-6R antibodies should block it

• Genetic validation approaches:

  • Compare antibody effects in IL-6 wild-type versus knockout systems

  • Use siRNA/shRNA to knockdown IL-6 or IL-6R expression and compare with antibody neutralization

• Epitope mapping:

  • Determine the precise epitope recognized by the antibody using techniques such as peptide mapping or hydrogen-deuterium exchange mass spectrometry

  • Epitope information provides insight into potential cross-reactivity and mechanism of action

What approaches are most effective for measuring IL-6 antibody stability and shelf-life?

Measuring IL-6 antibody stability and shelf-life requires comprehensive analytical approaches:

• Physical stability assessment:

  • Size-exclusion chromatography (SEC) to monitor aggregation over time

  • Dynamic light scattering (DLS) to detect changes in particle size distribution

  • Visual inspection for visible particles or turbidity

• Thermal stability analysis:

  • Differential scanning calorimetry (DSC) to determine melting temperature (Tm)

  • Circular dichroism (CD) spectroscopy to monitor changes in secondary structure

  • Thermal shift assays using fluorescent dyes that bind to hydrophobic regions exposed during unfolding

• Storage condition optimization:

  • Evaluate stability at different temperatures (−80°C, −20°C, 4°C, room temperature)

  • Test different buffer formulations (pH, ionic strength, excipients)

  • Assess freeze-thaw stability with multiple cycles

• Functional stability monitoring:

  • Periodic testing of binding activity using ELISA or BLI over the storage period

  • Neutralization assays (STAT3 phosphorylation, SAA induction) to confirm retention of biological activity

  • Compare activity to freshly prepared reference standards

• Accelerated stability studies:

  • Expose antibodies to elevated temperatures (e.g., 40°C) to predict long-term stability

  • Use Arrhenius equation to extrapolate shelf-life at normal storage conditions

  • Include forced degradation studies (extreme pH, oxidation, agitation) to identify degradation pathways

• Analytical characterization:

  • Mass spectrometry to monitor chemical modifications (oxidation, deamidation)

  • Capillary isoelectric focusing (cIEF) to assess charge heterogeneity

  • Peptide mapping to identify specific degradation sites

How are next-generation sequencing techniques advancing IL-6 antibody development?

Next-generation sequencing (NGS) techniques are revolutionizing IL-6 antibody development in several ways:

• Antibody repertoire analysis:

  • NGS enables comprehensive analysis of B-cell repertoires from immunized animals or human patients

  • Identification of naturally occurring anti-IL-6 antibody sequences with potential therapeutic applications

  • Discovery of rare antibody sequences that might be missed by traditional hybridoma approaches

• High-throughput screening integration:

  • Combining NGS with high-throughput functional screening accelerates identification of lead candidates

  • Parallel analysis of thousands of antibody sequences correlates with functional properties

  • Machine learning algorithms predict antibody characteristics based on sequence information

• Affinity maturation optimization:

  • NGS tracks the evolution of antibody sequences during in vitro affinity maturation

  • Identification of key mutations that enhance binding affinity or functional properties

  • Rational design of optimized antibodies based on sequence-function relationships

• Humanization process improvement:

  • NGS analysis of human antibody repertoires informs better humanization strategies

  • Identification of human framework regions that maintain stability while reducing immunogenicity

  • The development process of HZ-0408b illustrates this approach, where researchers selected human germline sequences for framework regions while preserving the complementarity-determining regions (CDRs) from the mouse antibody

• Epitope diversity analysis:

  • NGS-based epitope mapping identifies diverse binding sites on IL-6

  • Development of antibody panels targeting different epitopes for enhanced efficacy or combined approaches

What are the emerging alternative approaches to traditional IL-6 antibodies?

Several innovative approaches are emerging as alternatives to traditional IL-6 antibodies:

• Bispecific antibodies:

  • Antibodies that simultaneously target IL-6 and IL-6R or other inflammatory mediators

  • Dual-targeting approaches that combine IL-6 blockade with inhibition of complementary pathways (e.g., IL-1, TNF)

  • Enhanced efficacy through synergistic pathway inhibition

• Antibody-cytokine fusion proteins:

  • Fusion of anti-inflammatory cytokines to anti-IL-6 antibodies for localized immunomodulation

  • Targeted delivery of IL-10 or TGF-β to sites of IL-6-mediated inflammation

• Small molecule IL-6 pathway inhibitors:

  • Development of small molecules that disrupt IL-6/IL-6R interaction

  • JAK inhibitors that block downstream signaling pathways activated by IL-6 and other cytokines

  • Potential advantages in oral bioavailability and manufacturing cost

• RNA-based therapeutics:

  • siRNA or antisense oligonucleotides targeting IL-6 or IL-6R mRNA

  • miRNA modulators that regulate IL-6 expression or signaling

  • mRNA vaccines inducing antibodies against IL-6

• Nanobodies and alternative protein scaffolds:

  • Single-domain antibody fragments (nanobodies) against IL-6 with improved tissue penetration

  • Non-antibody protein scaffolds engineered to bind IL-6 with high affinity

  • Potential advantages in stability, production cost, and novel modes of action

How can researchers integrate computational approaches to optimize IL-6 antibody design?

Computational approaches offer powerful tools for optimizing IL-6 antibody design:

• Structure-based design:

  • Molecular modeling of IL-6/antibody complexes to predict binding interactions

  • In silico mutagenesis to identify modifications that enhance binding affinity

  • Structure-guided optimization of complementarity-determining regions (CDRs)

• Machine learning applications:

  • Prediction of antibody developability properties (solubility, stability, aggregation propensity)

  • Identification of sequence patterns associated with high affinity or functional activity

  • Virtual screening of antibody libraries to prioritize candidates for experimental testing

• Molecular dynamics simulations:

  • Analysis of dynamic interactions between antibodies and IL-6

  • Identification of flexible regions that affect binding kinetics

  • Optimization of conformational stability to improve shelf-life

• Network analysis of IL-6 signaling:

  • Systems biology approaches to model IL-6 signaling networks

  • Identification of optimal intervention points for antibody targeting

  • Prediction of downstream effects and potential compensatory mechanisms

• Immunogenicity prediction:

  • Computational tools to identify potential T-cell epitopes in antibody sequences

  • De-immunization strategies to reduce immunogenicity while maintaining function

  • Optimization of humanization processes using computational predictions

How are emerging single-cell technologies informing our understanding of IL-6 antibody mechanisms?

Single-cell technologies are providing unprecedented insights into IL-6 antibody mechanisms:

• Single-cell RNA sequencing (scRNA-seq):

  • Characterization of cell-specific responses to IL-6 stimulation and antibody treatment

  • Identification of heterogeneous cellular responses within seemingly homogeneous populations

  • Discovery of novel IL-6-responsive cell subsets and signaling pathways

• Single-cell proteomics:

  • Analysis of protein-level changes in response to IL-6 and anti-IL-6 antibodies

  • Correlation of surface receptor expression with sensitivity to IL-6 blockade

  • Identification of biomarkers predictive of response to IL-6 antibody therapy

• Single-cell secretome analysis:

  • Measurement of cytokine secretion from individual cells after IL-6 stimulation or blockade

  • Characterization of compensatory cytokine production following IL-6 inhibition

  • Identification of cell-specific secretory responses relevant to disease pathogenesis

• Spatial transcriptomics and proteomics:

  • Mapping IL-6 signaling and antibody effects within tissue microenvironments

  • Understanding cell-cell interactions that modulate responses to IL-6 antibodies

  • Visualization of antibody penetration and target engagement in tissues

• Cellular indexing of transcriptomes and epitopes (CITE-seq):

  • Simultaneous measurement of surface protein expression and transcriptional responses

  • Correlation of IL-6R expression levels with sensitivity to IL-6 antibodies

  • Identification of cellular subsets with differential responses to IL-6 blockade